AstraZeneca Signs a Worldwide Development and Commercialization Agreement with Daiichi Sankyo for $6.9B

 AstraZeneca Signs a Worldwide Development and Commercialization Agreement with Daiichi Sankyo for $6.9B

AstraZeneca Signs a Worldwide Development and Commercialization Agreement with Daiichi Sankyo for $6.9B

Shots:

  • Daiichi Sankyo to receive $1.35B upfront, $5.55B as regulatory & commercial milestones making the total deal value $6.9B. AstraZeneca to get WW co-development and co-commercialization rights for Daiichi’s trastuzumab deruxtecan (Ex- Japan) with equal cost & profit sharing
  • The focus of the collaboration is to develop trastuzumab deruxtecan for HER2+ breast and gastric cancer with the expansion of AstraZeneca’s Oncology portfolio
  • Trastuzumab deruxtecan (DS-8201) is ADC designed to deliver CT to cancer cells and has received FDA’s BT designation & MHLW’s Sakigake designation for HER2+ advanced or m-breast cancer & HER2-positive advanced gastric or gastroesophageal junction respectively with its expected FDA filling in Q2’19

 Click here to read full press release/ article | Ref: AstraZeneca | Image: AstraZeneca

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post